cyrilzakka/clinical-trials huggingface dataset:
Observatory on Emergency Care for Acute Coronary Syndrome in Grand Est of France

The purpose is to build up a data observatory of individuals with thoracic pain evoking acute coronary syndrome (ACS). The aim is the characterization of this population of patients consulting at emergency department, the evaluation of therapeutic strategies with regard to guidelines and the becoming of patients including severe complications and mortality.


Eligibility Criteria:
Inclusion Criteria:

* Resident in Grand Est of France (Lorraine, Champagne Ardenne) under medical care at the emergency room or outside of hospital or in cardiology:
* Outside of hospital: for thoracic or epigastric pain with suspicion of ACS Emergency: for thoracic pain for which the doctor will prescribe troponin or troponin kinetics
* Affiliation to social security

Exclusion Criteria:

* Patient affected by ACS with ST segment elevation
* Patient with traumatic thoracic pain
* Patient with thoracic pain of parietal origin
* Patient with consciousness troubles
Out-of-Hospital Intubation With Metal Single Use Laryngoscope Blades

New single use laryngoscope metal blades are available for intubation. This type of blade is safer than the reusable ones concerning the interhuman cross infection risk. No clinical studies have compared the two types of blades in the emergency context. The primary aim of this study is to demonstrate that single use blades are as efficient as the reusable ones concerning intubation conditions.

All adult patients requiring tracheal intubation in the pre hospital emergency context will be included. All intubation will be performed by an emergency physician or a nurse specialized in anesthesia. For patients with spontaneous cardiac activity, rapid sequence intubation will be performed to allow intubation.

Comparisons studied will be : Intubation success rate at the first laryngoscopy, glottis exposure assessed by Cormack and Lehane classification, difficult intubation rate assessed by the Intubation Difficult Score (IDS), the need for alternative airway techniques and the immediate post intubation complications rate as vomiting, dental trauma, pulmonary inhalation, arterial desaturation , hypotension episodes and cardiac arrest occurrence.

Eligibility Criteria:
Inclusion Criteria:

* All adult patients requiring out-of-hospital intubation

Exclusion Criteria:

* Patient under 18 years old
* Patients with criteria predictive of impossible intubation under direct laryngoscopy
Blood Collection for Research Related to Certain Diseases Involving Blood Vessels

The collection of human specimens from both patients and healthy volunteers is necessary for the development of laboratory assays to further basic and clinical research studies. This protocol defines the purposes for which specimens will be collected and establishes general conditions under which sample collection will be performed.

The collection of human specimens from both patients and healthy volunteers is necessary for the development of laboratory assays to further basic and clinical research studies. This protocol defines the purposes for which specimens will be collected and establishes general conditions under which sample collection will be performed.

Eligibility Criteria:
* INCLUSION CRITERIA:

Males or females of age 18 years and older can be included in the study.

EXCLUSION CRITERIA:

Individuals without sickle cell disease or other chronic anemias who wish to donate blood will be excluded if the hemoglobin is less than 10 g/dL for women or less than 12g/dL for men.

Individuals with sickle cell disease or other chronic anemias will be excluded from donating blood samples if the hemoglobin is less than 6 g/dL.

A participant s most recent CBC result, obtained in the past 12 months, will be used to determine eligibility.

There are no exclusion criteria for participants donating saliva or urine.
Coronary Drug Project Mortality Surveillance

To determine whether there were any long term sequelae of the drugs used in the Coronary Drug Project (estrogens, dextrothyroxine, nicotinic acid, clofibrate).

BACKGROUND:

Three of the CDP treatments (two doses of estrogen and dextrothyroxine) were stopped prematurely because of toxicity. At the time the treatments were stopped, it was thought that future assessment of the status of patients on those treatments would be important to evaluate long-term sequellae. Another clinical trial evaluating clofibrate for primary prevention found that more patients on that treatment than on placebo had died. This effect persisted even after the treatment was stopped. Therefore, it was considered necessary to follow the CDP patients on clofibrate.

Of the original 834l patients, about 6000 were still alive in March l975. Cause-specific mortality in those patients was assessed through March l980.

DESIGN NARRATIVE:

The vital status of the subjects known to be alive at the end of the CDP in March l975 was assessed as of March l980. This was accomplished through questioning the local investigators, letters to the subjects, and by use of Social Security Administration and National Death Index records.

The study completion date listed in this record was obtained from the Query/View/Report (QVR) System.

Eligibility Criteria:
No eligibility criteria
Characterization of the Pharmacodynamic Response to Vaped THC

This study aims to characterize the pharmacodynamic response to vaped THC in young adult, occasional cannabis users with respect to outcomes such as stimulation and sedative effects, mood, anxiety, and craving, as well as cognitive and objective outcomes such as heart rate and cortisol changes with THC vs placebo.

Enrollees will include 120 healthy, weekly or greater MJ users, aged 18-55. The study will be conducted according to a double-blind, placebo-controlled, random order, cross-over design, consisting of one 3-hour screening visit and 2 randomized, approximately 6-hour laboratory sessions. At the latter visits (following confirmation of eligibility), subjects will complete baseline questionnaires and assessments, including a driver simulator test, a blood draw, vitals, and an imaging session using functional near-infrared spectroscopy (fNIRS). Subjects will then vape a first dose (either THC or placebo based on randomization). Vitals and questionnaires will then be administered throughout the visit, at baseline, and at approximately 15, 60, 90, 130, 165, and 210 minutes post initial dose. Subjects will also perform fNIRS testing at baseline, 30, and 180 minutes and driver simulator at baseline, 60, and 90 minutes post initial THC/placebo administration. A drug recognition expert (DRE) will conduct a standard field sobriety test to identify impairment at approximately 130 minutes post dose. Following the initial dose vaped at 0 minutes, standardized reduced doses will be vaped approximately 30, 60, and 90 minutes later. Given the cross-over design of this study, participants will be assigned to receive THC or placebo at the first laboratory visit and will receive the other substance at the second laboratory visit.

Eligibility Criteria:
Inclusion Criteria:

* Men and women aged 18-55 years, inclusive.
* Competent and willing to provide written informed consent.
* Able to communicate in English language.
* Regular, at least weekly on average, marijuana use
* Self-reported ability to abstain from cannabis for 24 hours without withdrawal.

Exclusion Criteria:

* Any unstable, serious medical illness or cardiovascular disease/events.
* New or unstable psychiatric symptoms, schizophrenia, or bipolar I disorder.
* Diabetes, cirrhosis, renal failure, Hepatitis C, or HIV.
* History of syncope without an identified situational stressor, migraines \>1x/month, or head injury with prolonged unconsciousness (\> 24 hours).
* Daily use of benzodiazepines or barbiturates, antihistamines, atropine, scopolamine, or other strong anticholinergic agents.
* Current pregnancy, lactation or trying to become pregnant (confirmed by urine pregnancy test).
* History of substance abuse treatment and intent to quit or receiving treatment for cannabis use.
* Affective disorder in the past month or history of panic attacks.
* Smoking more than 10 tobacco cigarettes or equivalent e-cigarettes a day.
* In the opinion of the investigator, not able to safely participate in this study.
A Study of Mental Health Care in People With Cancer

The purpose of this study is to look at mental health services for adults with depressed mood who were diagnosed with cancer at the age of 65 or older. This study will compare the usual approach for connecting older adults with depressed mood to mental health services with the Open Door for Cancer (OD-C) approach. We will find out if the OD-C approach is practical and useful for cancer patients who participate in the intervention and for providers who see or treat cancer patients.


Eligibility Criteria:
Inclusion Criteria:

Patients

* Per medical record and/or self-report, diagnosed with breast, colorectal, lung, or prostate cancer at age 65 years or older
* Per medical record and/or self-report, undergoing active cancer treatment (e.g., radiation, chemotherapy, immunotherapy, surgery) or within six months of completing treatment
* Score of ≥5 on the Patient Health Questionnaire-9 (PHQ-9)
* Per self-report, fluent in English\*\* \*\* Language verification: Prior to enrollment, patients will be asked the following two questions by a Clinical Research Coordinator (CRC) to verify English fluency necessary for participation in the study:

  1. How well do you speak English? (must respond "very well" or "well" when given the choices of Very well, Well, Not well, Not at all, Don't know, or Refused)
  2. What is your preferred language for healthcare? (must respond English)

Providers

* Per self-report, works in oncology, nursing, social work, psychology, or psychiatry
* Per self-report, currently works in oncology at least 50% of the time
* Per self-report, provided cancer care for at least three years at time of consent
* Per self-report, fluent in English

Exclusion Criteria:

Patients

* Severely cognitively impaired as demonstrated by Blessed Orientation Memory Concentration scores of ≥ 11
* Per research staff judgment and/or self-report, too ill or weak to complete study procedures
* Per medical record and/or self-report, receiving hospice care at the time of enrollment
* Per medical record and/or self-report, currently enrolled in mental health treatment

Providers

* N/A
Hypertriglyceridemia Associated Acute Pancreatitis in Intensive Care Unit and Therapeutic Plasmapheresis

Acute pancreatitis (AP) is a one of the potentially life-threatening complication of severe hypertriglyceridemia (HTG), with mortality around to 30%.

HTG-associated PA and their complications management has to be the same as the other pancreatitis, but they are associated with the worse clinical outcomes. Triglycerides levels are correlated with the risk of pancreatitis and severity.

Therapeutic plasma exchange (TPE) could provide positive effects in reducing triglyceridemia plasma levels during the acute phase of HTG-AP, and in prevention of recurrence. There is currently no difference about mortality in studies. Some authors have recommended its use only in severe HTG-AP and have precised the need of early initiation to have positive results.

Despite such promising findings from studies, the effects of therapeutic plasma exchange on HTG-associated PA have never been specifically assessed and its benefits in critically ill patients with AP remains uncertain.


Eligibility Criteria:
Inclusion Criteria:

* Age \> 18 years
* Admission in ICU for acute pancreatitis associated with HTG

Exclusion Criteria : Patient without norepinephrine or missing data.

* Acute pancreatitis without HTG
* Patient already include in this study
* Patient opposed to use of his data
Discovery of New Early Detection Biomarkers of Acute Respiratory Distress Syndrome

The goal of this project is to find a series novel biomarkers by differential proteomic techniques that can improve the early diagnosis and develop a more efficient therapy to enhance ARDS patient survival rate.

Acute respiratory distress syndrome(ARDS) has a very poor prognosis and high mortality. To improve the early diagnosis of ARDS, there is an urgent need for novel biomarkers of ARDS. The goal of this project is to find a series novel biomarkers by differential proteomic techniques that can improve the early diagnosis and develop a more efficient therapy to enhance ARDS patient survival rate. Clinical data and blood sample were recorded before treatment and after treatment. Acute Physiology And Chronic Health Evaluation III (APACHE III) scores were calculated at enrolment. Studying blood specimens from different period ARDS patients by proteomic analysis. It can provide information on a complex composition of proteins that are differentially expressed, which could be used for discovering high sensitivity and specificity ARDS biomarker.

Eligibility Criteria:
Inclusion Criteria:

* The Berlin definition of acute respiratory distress syndrome
* ATS definition of severe pneumonia

Exclusion Criteria:

* age below 18 years
* pregnancy
* Expected survival under 24 hours
Effect of Strength Training on Executive Functions in Elderly People With Mild Cognitive Impairment

Cognitive impairment or dementia is their last degree in one of the main concerns at a social level in these ages. To this day, there are different pharmacological and non-pharmacological therapies that can help prevent deterioration, as in this case, physical exercise.

In the existing scientific literature, you can find a lot of information about the effect of aerobic exercise on cognition, but little is known about the effect of force exercise and its effect on general cognition and executive functions.

Therefore, in this research the investigators will investigate the effect of strength training in people over 60 with a diagnosis of mild cognitive impairment in executive functions. For this, a controlled and randomized clinical trial will be developed in the city of Seville

The training program will last 20 weeks and a frequency of 3 times / week.

During the week 0 the initial evaluation will be developed. Between weeks 1-20, the training program will be addressed. In week 21, all the changes made in all the measured variables will be evaluated.

Finally, in week 33 the variables will be measured again to see if the possible improvements given in the training program last over time.

The experimental group will perform a planned and individualized training with guided machines and training loads will be adjusted at the beginning of each week.

The control group will perform breathing and relaxation exercises to avoid a sample death.

After the intervention, there will be a follow-up phase for 3 months.

Eligibility Criteria:
Inclusion Criteria:

* The sample is made up of people over 60 years of age, who are not active professionally, speak and understand the Spanish language.
* In addition, they should be diagnosed with mild cognitive impairment. This will be evaluated by specialists through the minimental test (score between 24 and 28).
* On the other hand, they should not suffer from other serious psychiatric or neurodegenerative neurological diseases.
* In relation to mental health, it will be a reason for exclusion to have had 3 episodes of depression in the last 5 years or 10 episodes that have required some psychiatric or medical treatment.In addition,
* The people included must be postmenopausal

Exclusion Criteria:

* Participate in other physical exercise programs in a systematic way or in individualized and systematic programs in cognitive programs.
* Dispose of cardiovascular diseases, heart diseases that involve an absolute contradiction of physical exercise (unstable angina, severe auroventricular block) and cerebrovascular or have suffered a heart attack in the last 6 years.
* Have had seizures (More than 2 in the last 12 months).
* Consumption of alcohol 20 grams / day or 2 beers or wine glasses daily.
* Functional limitations (According to Functional activities Questionnaire)
* Being a musician or bilingual.
Dexamethasone Treatment of Congenital Adrenal Hyperplasia

The purpose of this study is to determine if dexamethasone given at night is a more effective treatment for congenital adrenal hyperplasia in young children than standard three times per day hydrocortisone. Our hypothesis is that nocturnal dexamethasone will lead to more efficient suppression of the hypothalamic-pituitary-adrenal axis. We performed a cross-over trial comparing hormonal control during two 24-hour hospitalizations, one on hydrocortisone and one on nocturnal dexamethasone.

This is a Phase II clinical trial, intended to estimate the effect of instituting Dexamethasone therapy in comparison to prior standard therapy. Each subject provides his own baseline data. There is no control group. Patients with CAH who meet inclusion criteria will be admitted to the clinical research center for two 24 hour hospitalizations. Adrenal hormone profiles will be measured during each hospitalization. The patient will take his or her baseline hydrocortisone regimen during one hospitalization and a new regimen consisting of a single daily nocturnal dose of Dexamethasone during the second hospitalization.

Eligibility Criteria:
Inclusion Criteria:

* Classic salt-wasting 21-hydroxylase deficient congenital adrenal hyperplasia
* Pre-pubertal children with bone ages below 8 years

Exclusion Criteria:

* Age less than 2 years
* Patients with additional medical conditions necessitating glucocorticoid therapy.
* Patients on phenytoin, barbiturates, and rifampin as these medications accelerate the metabolism of glucocorticoids.
* Patients on ketoconazole as this medication increases the bioavailability of glucocorticoids.
Study of Tocilizumab (RoActemre) Administered Subcutaneously in Participants With Rheumatoid Arthritis in Everyday Clinical Practice

ARATA is a prospective, non-interventional, multicenter, observational study in Germany to evaluate the long-term effectiveness and tolerability of subcutaneously administered tocilizumab in participants with rheumatoid arthritis in daily clinical practice. Participants will be followed over an observation period of up to 2 years after the initial injection.


Eligibility Criteria:
Inclusion Criteria:

* Participants who have not yet been treated with tocilizumab
* Participants who have received the first injection with tocilizumab maximum 1 month before inclusion in the study and the necessary baseline data and disease characteristics are present

Exclusion Criteria:

* Participants who at the time of the study inclusion are participating in a different interventional study on rheumatoid arthritis
Neonatal Antimicrobial Resistance and Outcome

This is a multicentre observational study involving NNUs across the UK. Study personnel (Neonatologists and research Nurses) from these NNUs will identify eligible babies in whom a positive culture has been obtained.

This study will help identify the infections leading to death in babies on UK neonatal units, define the clinical characteristics of babies dying from infections, and describe the management of babies dying from infections with a specific focus in their antimicrobial treatment.

The neonIN surveillance network captures data on episodes of invasive neonatal infection on a web-based database. Over 30 UK neonatal units currently contribute to this database in real-time. An episode of neonatal infection is defined as a positive culture collected from a normally sterile site such as the blood, cerebrospinal fluid (CSF) or urine (via catheter or suprapubic aspirate) for which clinicians prescribed at least five days of appropriate antibiotics. Clinical, demographic and microbiological data (including antimicrobial susceptibilities) are collected using a standardised online questionnaire. Denominator data regarding the total number of live-births and neonatal-admissions are collected for each neonatal unit.

Through our study we aim to understand and describe better those infections and risk factors that lead to death. The case-control study will enable us to determine if gaps in optimal management, such as the wrong antibiotic or the wrong dose, are associated with poor outcomes. We can then translate such information into practice and develop / improve clinical guidance in order to improve outcomes.

For the purpose of this study, we will request information on the baby's status (alive/died/not known) at 28 days after the positive culture was obtained. If the baby is alive, then this baby becomes eligible as a control. If the baby has died, then further details will be sought including the date of death and whether death was attributed to the infection.

Eligibility Criteria:
Inclusion criteria:

• Infants on participating NNUs who have an episode of infection with a positive culture.
Effect of Oral Isotretinoin on The Level of SerumYKL40 in Acne Vulgaris Patients

The aim of the study is to evaluate the effect of oral isotretinoin on SerumYKL40 in acne vulgaris patients.

Acne vulgaris is a common chronic inflammatory disease of the skin. It is found in about 80% of young adults and adolescents. It is a disease that affects the pilosebaceous units of the skin and may result in inflammatory or non-inflammatory lesions,Oral isotretinoin (13-cis-retinoic acid) is the only drug that counteracts all the pathogenetic mechanisms that contribute to the development of acne .The standard dose of isotretinoin is 0.5 to 1 mg/kg per day for 4 months to a cumulative dose of 120-140 mg/kg is effective in the management of acne vulgaris The scope of our study is to detect serum YKL-40 level in acne patient before and after oral isotretinoin treatment

Eligibility Criteria:
Inclusion Criteria:

1. Healthy persons of both sexes with moderate and severe acne.
2. Age above 14 years.

Exclusion Criteria:

1. Pregnant and lactating women, immunocompromised patients.
2. History of chronic liver disease, hyperlipidemia, non-inflammatory acne conditions, , history of neurologic disorders, history of neoplastic disorders, and history of cardiac disease.
3. History of systemic acne treatment for at least 4 weeks prior to inclusion and no topical treatments for at least 2 weeks.
4. Cases with known hypersensitivity reaction to isotretinoin.
iADAPT to Support Strategy Training After Stroke

Adherence to rehabilitation interventions is associated with functional outcomes (e.g. independence in daily activities, return of motor function) after stroke. Low adherence to rehabilitation home programs is common after stroke. Interventions delivered via mobile health applications demonstrated positive effects on adherence to health behaviors (e.g. medication routines, smoking cessation). The investigators developed the iADAPT mobile application to support adherence to Strategy Training. Strategy Training is an iterative rehabilitation intervention the promotes goal setting, planning, and self-monitoring after stroke. This study examines the effects of the iADAPT mobile health application relative to a workbook on adherence to Strategy Training after stroke.


Eligibility Criteria:
Inclusion Criteria:

-Diagnosis of Stroke

Exclusion Criteria:

* prior exposure to Strategy Training
* vision impairment that impairs ability to read device screen or worksheet
* poor self-awareness (score of ≥2 on Self Awareness of Deficits Inventory item #1 or #2
* current major depressive, bipolar, or psychotic disorder (Patient Health Questionnaire-9, PRIME-MD)
* current alcohol or drug abuse (Mini International Neuropsychiatric Interview)
* severe aphasia (score ≤1 on Boston Diagnostic Aphasia Examination)
* current diagnosis of dementia, neurodegenerative disease, or cancer
* anticipated discharge to a skilled nursing facility